BioXcel Therapeutics (BTAI) FCF Margin Growth (1y) (2023 - 2026)
BioXcel Therapeutics (BTAI) FCF Margin Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 427.00 |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 325.00 |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -892.00 |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 1,003.00 |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 410.00 |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 39.00 |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 333.00 |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.30 Mn | 24.30 Mn | 160,000.00 | 712,862.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 712,862.00 |
| Mar 31, 2026 | 143,593.00 |
| Dec 31, 2025 | -150,461.00 |
| Sep 30, 2025 | -1.15 Mn |
| Jun 30, 2025 | -838,007.00 |
| Mar 31, 2025 | -412,618.00 |
| Dec 31, 2024 | 309,824.00 |
| Sep 30, 2024 | 338,712.00 |
| Jun 30, 2024 | 626,108.00 |
| Mar 31, 2024 | 2.24 Mn |
| Dec 31, 2023 | 909,046.00 |
| Sep 30, 2023 | 1.17 Mn |